Second Theranos lab failed major inspection
Theranos Inc. failed a second major U.S. regulatory inspection of its laboratory facilities, people familiar with the situation said, a setback the Silicon Valley blood-testing firm hasn’t disclosed to investors or patients.And at TechCrunch, the headline story:
The failed regulatory inspection—at its one active lab at the time—has put the company at risk of a new round of sanctions, these people said.
The inspection, which took place in late September, came just days before Theranos said it was exiting the medical-testing business altogether, the people said. On Oct. 5, the closely held company said it would pivot to developing lab equipment to sell to other firms and restructure “around the model best aligned with our core values and mission,” according to a statement at the time.
The Centers for Medicare and Medicaid Services concluded its review of the second of Theranos’s two labs, in Scottsdale, Ariz., on Sept. 29 and found deficiencies there, the people familiar with the matter said....MORE